Immunotoxin therapy of cancer
Open Access
- 1 July 2006
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 6 (7), 559-565
- https://doi.org/10.1038/nrc1891
Abstract
Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.Keywords
This publication has 64 references indexed in Scilit:
- Current Views of Toll-Like Receptor Signaling PathwaysGastroenterology Research and Practice, 2010
- TLR4 Links Podocytes with the Innate Immune System to Mediate Glomerular InjuryJournal of the American Society of Nephrology, 2008
- Mechanisms of Disease: Toll-like receptors in cardiovascular diseaseNature Clinical Practice Cardiovascular Medicine, 2007
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJCI Insight, 2005
- A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphomaBlood, 2005
- Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13—PE38QQR for recurrent malignant gliomaJournal of Neurosurgery, 2005
- Monoclonal antibodies for brain tumour treatmentExpert Opinion on Biological Therapy, 2004
- The role of podocytes in glomerular pathobiologyClinical and Experimental Nephrology, 2003
- The IL-2/IL-2 receptor system: A current overviewCell, 1993
- Expression cloning of a diphtheria toxin receptor: Identity with a heparin-binding EGF-like growth factor precursorCell, 1992